Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

25 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A, Masliah-Planchon J, Callens C, Vacher S, Lecerf C, Frelaut M, Borcoman E, Torossian N, Ricci F, Hescot S, Sablin MP, Tresca P, Loirat D, Melaabi S, Trabelsi-Grati O, Pierron G, Gentien D, Bernard V, Vincent Salomon A, Servant N, Bieche I, Le Tourneau C, Kamal M. Moreira A, et al. Among authors: melaabi s. Eur J Cancer. 2019 Nov;121:202-209. doi: 10.1016/j.ejca.2019.09.001. Epub 2019 Oct 5. Eur J Cancer. 2019. PMID: 31593830
Relevance of a molecular tumour board (MTB) for patients' enrolment in clinical trials: experience of the Institut Curie.
Basse C, Morel C, Alt M, Sablin MP, Franck C, Pierron G, Callens C, Melaabi S, Masliah-Planchon J, Bataillon G, Gardrat S, Lavigne M, Bonsang B, Vaflard P, Pons Tostivint E, Dubot C, Loirat D, Marous M, Geiss R, Clément N, Schleiermacher G, Kamoun C, Girard E, Ardin M, Benoist C, Bernard V, Mariani O, Rouzier R, Tresca P, Servois V, Vincent-Salomon A, Bieche I, Le Tourneau C, Kamal M. Basse C, et al. Among authors: melaabi s. ESMO Open. 2018 Apr 6;3(3):e000339. doi: 10.1136/esmoopen-2018-000339. eCollection 2018. ESMO Open. 2018. PMID: 29636991 Free PMC article.
A large collection of integrated genomically characterized patient-derived xenografts highlighting the heterogeneity of triple-negative breast cancer.
Coussy F, de Koning L, Lavigne M, Bernard V, Ouine B, Boulai A, El Botty R, Dahmani A, Montaudon E, Assayag F, Morisset L, Huguet L, Sourd L, Painsec P, Callens C, Chateau-Joubert S, Servely JL, Larcher T, Reyes C, Girard E, Pierron G, Laurent C, Vacher S, Baulande S, Melaabi S, Vincent-Salomon A, Gentien D, Dieras V, Bieche I, Marangoni E. Coussy F, et al. Among authors: melaabi s. Int J Cancer. 2019 Oct 1;145(7):1902-1912. doi: 10.1002/ijc.32266. Epub 2019 Apr 4. Int J Cancer. 2019. PMID: 30859564
ESR1 mutations: a new biomarker in breast cancer.
Carausu M, Bidard FC, Callens C, Melaabi S, Jeannot E, Pierga JY, Cabel L. Carausu M, et al. Among authors: melaabi s. Expert Rev Mol Diagn. 2019 Jul;19(7):599-611. doi: 10.1080/14737159.2019.1631799. Epub 2019 Jun 19. Expert Rev Mol Diagn. 2019. PMID: 31188645 Review.
A single droplet digital PCR for ESR1 activating mutations detection in plasma.
Jeannot E, Darrigues L, Michel M, Stern MH, Pierga JY, Rampanou A, Melaabi S, Benoist C, Bièche I, Vincent-Salomon A, El Ayachy R, Noret A, Epaillard N, Cabel L, Bidard FC, Proudhon C. Jeannot E, et al. Among authors: melaabi s. Oncogene. 2020 Apr;39(14):2987-2995. doi: 10.1038/s41388-020-1174-y. Epub 2020 Feb 10. Oncogene. 2020. PMID: 32042112
Combination of PI3K and MEK inhibitors yields durable remission in PDX models of PIK3CA-mutated metaplastic breast cancers.
Coussy F, El Botty R, Lavigne M, Gu C, Fuhrmann L, Briaux A, de Koning L, Dahmani A, Montaudon E, Morisset L, Huguet L, Sourd L, Painsec P, Chateau-Joubert S, Larcher T, Vacher S, Melaabi S, Salomon AV, Marangoni E, Bieche I. Coussy F, et al. Among authors: melaabi s. J Hematol Oncol. 2020 Feb 22;13(1):13. doi: 10.1186/s13045-020-0846-y. J Hematol Oncol. 2020. PMID: 32087759 Free PMC article.
Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants.
Villy MC, Masliah-Planchon J, Melaabi S, Trabelsi Grati O, Girard E, Bataillon G, Vincent-Salomon A, Le Gall J, Golmard L, Stoppa-Lyonnet D, Bieche I, Colas C. Villy MC, et al. Among authors: melaabi s. Gynecol Oncol Rep. 2021 Sep 2;37:100855. doi: 10.1016/j.gore.2021.100855. eCollection 2021 Aug. Gynecol Oncol Rep. 2021. PMID: 34541275 Free PMC article.
A Naive Lung Adenocarcinoma Harboring G1269A ALK Resistance Mutation.
Trabelsi-Grati O, El-Alam E, Melaabi S, Allory Y, Bièche I, Girard N, Callens C. Trabelsi-Grati O, et al. Among authors: melaabi s. JTO Clin Res Rep. 2020 Apr 28;1(3):100047. doi: 10.1016/j.jtocrr.2020.100047. eCollection 2020 Sep. JTO Clin Res Rep. 2020. PMID: 34589943 Free PMC article. No abstract available.
25 results